Report Overview

The Insulin market size in Kenya stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

Insulin is a life-saving medicine for people with typediabetes and is used to manage an increasing number of people with typediabetes. Serious complications result from suboptimal treatment, including blindness, amputations and premature death. Therefore, access to insulin is vital. Diabetes is the most common glycogen metabolism disorder in Kenya. The World Health Organization (WHO) estimates the prevalence of diabetes in Kenya at 3.3% and predicts a rise to 4.5% by 2025. However, two-thirds of diabetics may be undiagnosed. Higher rates of diabetics are found in urban areas. Urbanisation and adoption of Western lifestyles have led many Kenyans towards risk for developing DM. Around 22.6% patients are estimated to be using insulin in Nairobi, Kenya.



Market Drivers

The market is majorly driven by the increasing prevalence of Diabetes in Kenya. About 1% of deaths in Kenya were directly attributable to diabetes in 2012.

Increasing initiatives by Government of Kenya by Implementation of National Diabetes Strategy in 2015 has led to establishment of hospital diabetes clinics in nine provinces of the country. A Diabetes Education Programme has also been implemented for healthcare staff.

Overall, Rise in the prevalence of diabetes, increased initiatives by private pharmaceutical companies and partnerships with Government and increase in the healthcare expenditure are fuelling growth in insulin market in Kenya.

Non-adherence to treatment, high cost of Insulin and inaccessibility of insulin to rural population of Kenya are some of the restricting factors for growth of the insulin market in Kenya.

Storage of insulin vials is also a challenge as it needs to be stored at low temperatures between 2-8 degrees Celsius for the drug to work effectively. This requires access to refrigerators for health facilities or pharmacies storing them.